McDonald’s Corp. has finally updated its antibiotics policy that calls for reduced antibiotic usage after a two-year delay.
The fast-food giant’s new policy revealed in Decemebr follows guidelines set out by the World Health Organization (WHO), the World Organization for Animal Health, and other public and animal health groups.
According to McDonald’s, they will focus on the responsible use of medically important antibiotics and be aligned with WHO Guidelines on Antimicrobial Resistance.
The company added that its policy does not permit the routine use of medically important antibiotics for growth promotion or tdisease prevention.
It is committed to usage reduction, where possible without adverse effects on animal health and welfare.
The company has established market-specific targets for the responsible use of antibiotics for 10 in-scope markets, representing over 80 percent of its global beef supply chain.
In 2023, McDonald’s plans to share an update on its antibiotic usage.
However, the Natural Resources Defense Council (NRDC) criticized McDonald’s for failing to detail a rollout plan or a completion date to ensure accountability across the supply chain.
According to Lena Brook, director of food campaigns at NRDC, it is especially disappointing given that McDonald’s, the world’s largest beef buyer, chose optics over substance with its new beef policy update despite the urgency of the global antibiotic resistance crisis.
McDonald’s earned a grade of C from the NDRC for its previous policy. NDRC called McDonald’s updated policy a “new, weaker approach.”


FDA Approves Mitapivat for Anemia in Thalassemia Patients
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 



